We thank Mari Koivisto, Department of Biostatistics, University of Turku, Finland for help with the statistical analyses. Conflict of interest statement: AK has participated as a member in advisory boards of Pfizer, GlaxoSmithKline and Novartis and received honorarium from these. She has acted as a consultant to Crucell on vaccination immunology and been reimbursed for giving lectures by GPCR Compound Library concentration Crucell, GSK and Bayer. SHP and JMK declare no conflicts of interest. “
“Meningitidis and sepsis caused by serogroup B meningococcus are two severe diseases that
continue to cause significant mortality [1] and [2]. Five major pathogenic serogroups have been identified on the basis of the chemical composition of the bacterial capsule (A, B, C, Y and W135) [3], [4] and [5]. selleck chemical However, the capsular vaccine approach is not suitable for strains of serogroup B since that polysaccharide capsule
has a structural homology to human embryonic neural tissue [6]. Thus, outer membrane proteins or outer membrane vesicles (OMV)-based vaccines were tested extensively in clinical trials [7]. An alternative approach to vaccine development is based on surface-exposed proteins contained in outer membrane vesicles [4], [8] and [9]. OMV are released from the outer membrane of Gram negative bacteria. They consist of a phospholipid (PL) bilayer containing outer membrane proteins, lipopolysacchharide
(LPS) and periplasmic constituents [10]. These vesicles are made up of five major proteins. Besides, there is the protein NadA and, depending on the conditions of cultivation, the iron regulated proteins (IRP) [11], [12] and [13]. Furthermore, it is worth mentioning that OMV are also employed as carriers of polysaccharides in conjugated vaccines against Haemophilus influenzae and in vaccines against pneumonia [14] and [15]. A common antimeningococcal vaccine project against meningitis B and C had proposed a vaccine containing outer membrane vesicles (OMV) from Neisseria meningitidis B expressing iron regulated proteins (IRP) from a strain with high incidence in Brazil (N 44/89). The lipooligosaccharide (LOS endotoxin) of OMV is high others toxic. However residual LOS amounts are needed to maintain vesicle structure and adjuvate the immune response. Many studies have been carried out previously on other aspects of vaccine development, such as: the production process of N. meningitidis C [16], [17] and [18]; the evaluation of the importance of a second serogroup B strain as vaccine component [19]; the obtainment of vesicles with appropriate characteristics (with IRP expression and with low level of LOS) [20] and [21]; and the conjugation process of N. meningitidis C polysaccharide with N. meningitidis B OMV [22] and [23]. The objective of this study was to investigate the N.
Related posts:
- McMaster University, Hamilton, Ontario, Canada Medulloblastoma wi
- Benazepril RAAS inhibitor was approved by the Ethics Committee of the University
- BMS-536924 IGF-1R inhibitor transfected with the EGFRvIII
- CI-1040 212631-79-3 Including Controlled Lich The expression of V-ATPase subunit
- Specifically, it can be important to target newly synthesized pro